Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase II Clinical Study Evaluating the Efficacy and Safety of Cadonilimab Combined With Lenvatinib as Neoadjuvant Therapy in Renal Cell Carcinoma Patients With Partial Nephrectomy Indications But High Surgical Risk

NCT06138496 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06138496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06138496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase II Clinical Study Evaluating the Efficacy and Safety of Cadonilimab Combined With Lenvatinib as Neoadjuvant Therapy in Renal Cell Carcinoma Patients With Partial Nephrectomy Indications But High Surgical Risk
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2023
Completion date
December 31, 2025
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clear cell renal cell carcinoma